TERN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 106791 min ago

@ $6.86

Išleistas: 14 vas. 2024 @ 16:30

Grąža: -28.43%

Ankstesnis signalas: vas. 9 - 22:54

Ankstesnis signalas: Pirkimas

Grąža: -0.72 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	495 961
Vidutinė apimtis	896 139
Rinkos kapitalizacija	317.44M
EPS	$0 ( 2024-03-25 )
Kita pelno data	( $-0.360 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.87
ATR14	$0.00900 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Vivo Opportunity, Llc	Sell	136 255	Common Stock
2024-04-02	Vivo Opportunity, Llc	Sell	76 346	Common Stock
2024-04-03	Vivo Opportunity, Llc	Sell	103 870	Common Stock
2024-04-01	Vivo Opportunity, Llc	Sell	39 411	Common Stock
2024-04-02	Vivo Opportunity, Llc	Sell	22 084	Common Stock

INSIDER POWER
68.20
Last 96 transactions
Buy: 25 215 859 \| Sell: 2 318 163

Tūris Koreliacija

Ilgas: 0.60 (weak)

Trumpas: -0.48 (neutral)

Signal:(69.062) Neutral

Terns Pharmaceuticals, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SVAC	0.926
EMLD	0.908
ARTEU	0.905
CFFE	0.905
PAIC	0.898
LRMR	0.898
GDST	0.897
ARIZ	0.896
CARG	0.892
LQDA	0.891

10 Labiausiai neigiamai susiję koreliacijos
BCAB	-0.929
ATAI	-0.923
CUTR	-0.923
SMFL	-0.92
GMAB	-0.919
MYSZ	-0.919
SRAC	-0.916
SPCX	-0.908
VFF	-0.906
NCBS	-0.903

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Terns Pharmaceuticals, Koreliacija - Valiuta/Žaliavos

-0.10
( neutral )

-0.09
( neutral )

0.00
( neutral )

-0.30
( neutral )

-0.14
( neutral )

-0.41
( neutral )

Terns Pharmaceuticals, Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-881 000 (0.00 %)
EPS:	$-1.270

FY	2023
Pajamos:	$0
Bruto pelnas:	$-881 000 (0.00 %)
EPS:	$-1.270

FY	2022
Pajamos:	$0
Bruto pelnas:	$-1.03M (0.00 %)
EPS:	$-1.670

FY	2021
Pajamos:	$1.00M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.21

Financial Reports:

No articles found.

Terns Pharmaceuticals,

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.